Phreesia (NYSE:PHR) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Phreesia (NYSE:PHR) released its quarterly earnings data on Wednesday. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.08, Zacks reports. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. Phreesia updated its FY 2026 guidance to EPS.

Phreesia Stock Up 3.1 %

Shares of Phreesia stock traded up $0.72 during midday trading on Wednesday, hitting $23.95. The company’s stock had a trading volume of 833,076 shares, compared to its average volume of 408,588. The firm has a market capitalization of $1.39 billion, a P/E ratio of -16.29 and a beta of 1.03. Phreesia has a 1-year low of $17.07 and a 1-year high of $30.53. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. The stock has a 50-day simple moving average of $27.34 and a 200-day simple moving average of $23.99.

Insider Buying and Selling

In other news, SVP Amy Beth Vanduyn sold 1,311 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $26.61, for a total value of $34,885.71. Following the completion of the sale, the senior vice president now directly owns 115,633 shares of the company’s stock, valued at $3,076,994.13. This represents a 1.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael Weintraub sold 20,565 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $25.04, for a total transaction of $514,947.60. Following the transaction, the director now directly owns 242,827 shares in the company, valued at $6,080,388.08. The trade was a 7.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 183,887 shares of company stock valued at $5,146,862. Corporate insiders own 5.80% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Needham & Company LLC restated a “buy” rating and issued a $29.00 price target on shares of Phreesia in a research note on Friday, January 10th. Truist Financial lifted their target price on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Robert W. Baird reduced their price target on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. KeyCorp raised their price target on Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday, January 8th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $30.00 price objective on shares of Phreesia in a report on Tuesday, December 10th. Thirteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Phreesia has an average rating of “Buy” and an average target price of $31.15.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.